ThinPrep Pap Test Offers Improved Slide Preparation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System for cervical cancer screening has received FDA approval and is now available. The system offers an improved method of preparing Pap smears over the conventional method, leading to fewer retests due to compromised smears and potentially fewer missed abnormalities.

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System forcervical cancer screening has received FDA approval and is nowavailable. The system offers an improved method of preparing Papsmears over the conventional method, leading to fewer retestsdue to compromised smears and potentially fewer missed abnormalities.

With the ThinPrep Pap test, the physician collects the cervicalcells in the traditional way, but rather than smearing a smallportion of the cells onto a slide, the physician rinses the cellsfrom the collection device into a vial filled with preservativesolution. This vial is then sent to the lab where the ThinPrep2000 Processor disperses and filters its contents to reduce mucus,blood, and inflammation, and applies a thin, even layer of cellsto a microscope slide.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.